Details of the Drug Combinations

General Information of This Drug (ID: DMUP5Z0)

Drug Name

Nirogacestat DMUP5Z0

Synonyms

PF-03084014; 1290543-63-3; PF-03084014; PF-3084014; UNII-QZ62892OFJ; 865773-15-5; PF 3084014; PF-03084014 (PF-3084014); QZ62892OFJ; Z-3181; PF03084014; Nirogacestat [USAN]; Nirogacestat (USAN/INN); GTPL7746; SCHEMBL13184754; CHEMBL1770916; EX-A855; DTXSID60235679; MolPort-039-193-852; (2S)-2-[[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-N-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide; ZINC38217837; s8018; AKOS030526383; SB16726; DB12005; CS-1689; NCGC00378713-01

Indication

Disease Entry	ICD 11	Status	REF
Desmoid tumour	2F7C	Approved	[1]
Alzheimer disease	8A20	Phase 2	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
PF-03084014 + PF-03084014	DCUQHXW	PF-03084014	Triple Negative Breast Neoplasms	[4]
------------------------------------------------------------------------------------

References

1	FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217677
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7746).
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	ClinicalTrials.gov (NCT02299635) A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations